Abstract: TH-PO0481
Nefecon Plus Systemic Telitacicept for IgAN: Early Proteinuria Improvement in a Propensity Score-Matched Cohort
Session Information
- Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - IgAN
October 22, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- He, Lijie, Department of Nephrology, Xijing Hospital, Air Force Medical University, Xi’an, China
- Wu, Mengting, Department of Nephrology, Xijing Hospital, Air Force Medical University, Xi’an, China
Background
IgA nephropathy (IgAN) is a common primary glomerulonephritis with limited treatment options. Target-released budesonide target gut mucosal immunity, and telitacicept suppresses plasma cell and mature B cell. Their combination is theoretically synergistic but lacks clinical validation. This study compares the efficacy and safety of Nefecon plus telitacicept versus Nefecon alone in IgAN.
Methods
This prospective cohort study compared Nefecon with Nefecon plus telitacicept with 1:2 propensity score matching baseline age, gender, and proteinuria. Outcomes included changes in proteinuria and eGFR along with exploratory hematuria and safety.
Results
69 patients enrolled: 22 received monotherapy, 14 combination therapy (Figure 1). All patients completed 3-month follow-up; 14 in the monotherapy and 8 in the combination group completed 6-month follow-up. At 3 months, the combination group showed a significant reduction in proteinuria compared with monotherapy (geometric mean 711 vs. 1579 mg/24h, p=0.023). From months 3 to 6, both groups declined at similar rates. eGFR remained stable in both groups except for a transient increase at 3 months in the monotherapy group (p=0.030). Hematuria showed no significant differences (Figure 2). No serious adverse events occurred (Table 1).
Conclusion
This combination regimen may reduce proteinuria earlier in IgAN with high baseline proteinuria, with acceptable safety.